特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
666024

腎癌治療薬市場:市場規模、シェア、動向分析 - 治療薬クラス(標的療法、免疫療法)、薬理クラス、国別 2016年~2022年

Kidney Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Pharmacologic Class, By Country, And Segment Forecasts, 2016 - 2022

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 99 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
腎癌治療薬市場:市場規模、シェア、動向分析 - 治療薬クラス(標的療法、免疫療法)、薬理クラス、国別 2016年~2022年
出版日: 2018年06月18日
発行: Grand View Research, Inc.
ページ情報: 英文 99 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腎癌治療薬市場は、2016年から2022年にかけて5.4%のCAGRで推移し、2022年までに63億米ドル規模の市場に成長することが予測されています。新薬の入手性や、強力なパイプラインの存在、喫煙・飲酒、高齢者人口の増加などによって当市場の成長が促進されています。

当レポートでは、腎癌治療薬市場を調査し、疾患の概要、疫学、市場シェア、市場規模の推移と予測、市場動向、成長要因・阻害要因の分析、パイプライン情勢、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法

  • 情報調達
  • データ分析

第2章 エグゼクティブサマリー

第3章 疾患のプライマーと疫学

  • 病気のプライマー
  • 疫学

第4章 世界市場の概要

  • 腎癌治療薬市場:治療薬クラス別
  • 市場規模と予測
  • 市場シェア分析
  • 販売実績:薬理学クラス別
  • 市場動向とブランド戦略
  • 特許満了の分析
  • 腎癌治療薬市場:成長要因と阻害要因
  • M&A、取引情勢
  • バイオシミラーの進化
  • 新興市場
  • 償還シナリオ
  • SWOT分析

第5章 パイプライン情勢

  • パイプライン概要
  • パイプライン予測

第6章 企業プロファイル

  • Pfizer
  • Novartis
  • Bayer
  • Genentech
  • Bristol-Myers Squibb
  • Exelixis
  • エーザイ
  • Prometheus Labs

第7章 市場の見通し

  • 将来展望
  • 勝者と敗者
  • 新興企業と技術プラットフォーム
  • 前途
図表

List of Tables

  • TABLE 1 Incidence Rate per 100,000 in Seven Major Markets
  • TABLE 2 Incidence Rate per 100,000 in Forecast, Spain
  • TABLE 3 Marketed Drugs for Kidney Cancer
  • TABLE 4 Marketed Drugs for Kidney Cancer
  • TABLE 5 Sales Performance by Therapeutic Class, 2016 - 22
  • TABLE 6 Sales Performance by Market, in USD million, 2016 - 22
  • TABLE 7 Sales Performance by Market, by Pharmacologic Class, 2016 - 22
  • TABLE 8 Sales Performance by Pharmacologic Class, 2016 - 22
  • TABLE 9 U.S. Patents for Current Kidney Cancer Drugs
  • TABLE 10 Avastin (bevacizumab) Biosimilars Across Various Indications
  • TABLE 11 R&D Pipeline Overview
  • TABLE 12 Late Stage Pipeline
  • TABLE 13 Bavencio
  • TABLE 14 Tecentriq
  • TABLE 15 Fotivda
  • TABLE 16 Epacadostat
  • TABLE 17 Rocapuldencel-T
  • TABLE 18 Pipeline Forecast
  • TABLE 19 Pfizer Sales Forecast, 2016 - 2022
  • TABLE 20 Pfizer Pipeline
  • TABLE 21 Novartis Sales Forecast, 2016 - 2022
  • TABLE 22 Bayer Sales Forecast, 2016 - 2022
  • TABLE 23 Bayer Pipeline
  • TABLE 24 Genentech (Roche) Sales Forecast, 2016 - 2022
  • TABLE 25 Genentech (Roche) Pipeline
  • TABLE 26 Bristol-Myers Squibb Sales Forecast, 2016 - 2022
  • TABLE 27 Bristol-Myers Squibb Pipeline
  • TABLE 28 Exelixis Sales Forecast, 2016 - 2022
  • TABLE 29 Exelixis Pipeline
  • TABLE 30 Eisai Sales Forecast, 2016 - 2022
  • TABLE 31 Prometheus Labs Sales Forecast, 2016 - 2022

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Race and Gender Specific Prevalence of RCC in the U.S.
  • FIG. 8 Gender Specific Incidence Rate per 100,000 in the U.K. (1993 - 2014)
  • FIG. 9 Kidney Cancer Drugs Market Share, by Therapeutic Class, 2016 - 22
  • FIG. 10 Regional Market Size, 2016 - 2022
  • FIG. 11 Market Shares Distribution, 2016 - 2022
  • FIG. 12 Sales by Pharmacologic Class, 2016 - 2022
  • FIG. 13 Kidney Cancer SWOT
  • FIG. 14 Pfizer SWOT Analysis
  • FIG. 15 Novartis SWOT Analysis
  • FIG. 16 Bayer SWOT Analysis
  • FIG. 17 Genentech SWOT Analysis
  • FIG. 18 Bristol-Myers Squibb SWOT Analysis
  • FIG. 19 Exelixis SWOT Analysis
  • FIG. 20 Eisai SWOT Analysis
  • FIG. 21 Prometheus Labs SWOT Analysis
目次
Product Code: GVR-2-68038-514-4

The global kidney cancer drugs market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Grand View Research, Inc., registering a CAGR of 5.4% during the forecast period. Market growth is largely driven by factors such as availability of novel drugs and presence of a strong pipeline. Growth can also be attributed to rise in incidence of renal cancer due to growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.

In 2012, kidney cancer was the 13th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.

Further key findings from the report suggest:

  • Increasing incidence of the disease and rising geriatric population globally are amongst major factors stimulating market growth
  • Novel agents have expanded market opportunities through larger number of patients under treatment and better treatment prospects compared to traditional therapies. The notable clinical profile of immuno-oncology drugs is reflected their rapid uptake and expansion of indications
  • The current treatment landscape in metastatic and advanced RCC will shift from TKI and mTOR inhibitors to specific immuno-oncology agents like immune checkpoint inhibitors (ICI), which have demonstrated positive results on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy)
  • U.S. accounted for more than 35.0% of the market in 2016 due to increasing incidence of renal cell carcinoma and presence of key manufacturers in the country. On the other hand, surge in kidney cancer screening is a key driver in markets such as EU
  • Emerging markets in Asia Pacific and Middle East and Africa are fueled by increasing expenditure on healthcare, a large untapped patient population base due to rise in elderly population, and improvement in diagnostic technologies

Some of the key players operating in this market are: Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase market share.

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1. Disease Primer
  • 3.2. Epidemiology

Chapter 4 Global Market Overview

  • 4.1 Market by Therapeutic Class
  • 4.2 Market Size and Forecast 2016 - 2022
  • 4.3 Market Share Distribution, by Company 2016 - 2022
  • 4.4 Sales Performance, by Pharmacologic Class
  • 4.5 Market Dynamics and Brand Strategies
  • 4.6 Patent Expiry Analysis
  • 4.7 Kidney Cancer Drugs Market: Drivers and Restraints
    • 4.7.1 Drivers
    • 4.7.2 Challenges
  • 4.8 M&A, Deal Landscape (2013 - 2017 YTD)
    • 4.8.1 Mergers & Acquisitions
    • 4.8.2 Deals Landscape
  • 4.9 Evolution of Biosimilars
  • 4.10 Emerging Markets
  • 4.11 Reimbursement Scenario
  • 4.12 Kidney Cancer Sector SWOT

Chapter 5 Pipeline Intelligence

  • 5.1. Pipeline Landscape
    • 5.1.1 Leading Drugs in Development
    • 5.1.2 Key R&D Trends
  • 5.2 Pipeline Landscape
    • 5.2.1 Late Stage Pipeline and Sales Forecast
    • 5.2.2 Profiles of Disruptive Drugs
  • 5.3 Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1 Pfizer
    • 6.1.1 Company Overview
    • 6.1.2 Current Product Portfolio
    • 6.1.3 Product Sales Forecast Through 2022
    • 6.1.4 Strategic Initiatives
      • 6.1.4.1 Key Company News Flow
      • 6.1.4.2 Catalysts & Events Calendar
    • 6.1.5 Pipeline Analysis & Overview
    • 6.1.6 SWOT
  • 6.2 Novartis
    • 6.2.1 Company Overview
    • 6.2.2 Current Product Portfolio
    • 6.2.3 Product Forecast Sales Through 2022
    • 6.2.4 Strategic Initiatives
      • 6.2.4.1 Key Company News Flow
    • 6.2.5 Pipeline Analysis & Overview
    • 6.2.6 SWOT
  • 6.3 Bayer
    • 6.3.1 Company Overview
    • 6.3.2 Current Product Portfolio
    • 6.3.3 Product Forecast Sales Through 2022
    • 6.3.4 Strategic Initiatives
      • 6.3.4.1 Key Company News Flow
    • 6.3.5 Pipeline Analysis & Overview
    • 6.3.6 SWOT
  • 6.4 Genentech
    • 6.4.1 Company Overview
    • 6.4.2 Current Product Portfolio
    • 6.4.3 Product Forecast Sales Through 2022
    • 6.4.4 Strategic Initiatives
      • 6.4.4.1 Key Company News Flow
      • 6.4.4.2 Catalysts & Events Calendar
    • 6.4.5 Pipeline Analysis & Overview
    • 6.4.6 SWOT
  • 6.5 Bristol-Myers Squibb
    • 6.5.1 Company Overview
    • 6.5.2 Current Product Portfolio
    • 6.5.3 Product Forecast Sales Through 2022
    • 6.5.4 Strategic Initiatives
      • 6.5.4.1 Key Company News Flow
      • 6.5.4.2 Catalysts & Events Calendar
    • 6.5.5 Pipeline Analysis & Overview
    • 6.5.6 SWOT
  • 6.6 Exelixis
    • 6.6.1 Company Overview
    • 6.6.2 Current Product Portfolio
    • 6.6.3 Product Forecast Sales Through 2022
    • 6.6.4 Strategic Initiatives
      • 6.6.4.1 Key Company News Flow
      • 6.6.4.2 Catalysts & Events Calendar
    • 6.6.5 Pipeline Analysis & Overview
    • 6.6.6 SWOT
  • 6.7 Eisai
    • 6.7.1 Company Overview
    • 6.7.2 Current Product Portfolio
    • 6.7.3 Product Forecast Sales Through 2022
    • 6.7.4 Strategic Initiatives
      • 6.7.4.1 Key Company News Flow
    • 6.7.5 Pipeline Analysis & Overview
    • 6.7.6 SWOT
  • 6.8 Prometheus Labs
    • 6.8.1 Company Overview
    • 6.8.2 Current Product Portfolio
    • 6.8.3 Product Forecast Sales Through 2022
    • 6.8.4 Strategic Initiatives
      • 6.8.4.1 Key Company News Flow
    • 6.8.5 SWOT

Chapter 7 Market Outlook

  • 7.1 What the Future Holds
  • 7.2 The Winners and Losers
    • 7.2.1 Winners
    • 7.2.2 Losers
  • 7.3 Emerging Companies & Technology Platforms
  • 7.4 The Road Ahead
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.